Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy

Journal of Diabetes and its Complications

Volumn 20, Issue 6, 2006, Pages 367-370

  Ando, Hitoshi ^a   Takamura, Toshinari ^a   Nagai, Yukihiro ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetic neuropathy; Epalrestat; Erythrocyte sorbitol level

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; INSULIN; ORAL ANTIDIABETIC AGENT; POLYOL; SORBITOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE LEVEL; FEMALE; FUNCTION TEST; HUMAN; MALE; NERVE CONDUCTION; NERVE FUNCTION; PREDICTION; PRIORITY JOURNAL; VIBRATION; VOMITING;

AGED; ALDEHYDE REDUCTASE; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVES; PROGNOSIS; RHODANINE; SORBITOL; THIAZOLIDINES; TREATMENT OUTCOME;

EID: 33750315725     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.09.002     Document Type: Article

References (18)

1. Asano T., Saito Y., Kawakami M., Yamada N., Sekino H., Hasegawa S., and Fidarestat Clinical Pharmacology Study Group. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860). Journal of Diabetes and Its Complications 18 (2004) 336-342
2. Brown M.J., Bird S.J., Watling S., Kaleta H., Hayes L., Eckert S., and Foyt H.L. Natural progression of diabetic peripheral neuropathy in the zenarestat study population. Diabetes Care 27 (2004) 1153-1159
3. Dyck P.J. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle & Nerve 11 (1988) 21-32
4. Goto Y., Hotta N., Shigeta Y., Sakamoto N., and Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomedicine & Pharmacotherapy 49 (1995) 269-277
5. Greene D.A., Arezzo J.C., and Brown M.B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53 (1999) 580-591
6. Greene D.A., Brown M.J., Braunstein S.N., Schwartz S.S., Asbury A.K., and Winegrad A.I. Comparison of clinical course and sequential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials. Diabetes 30 (1981) 139-147
7. Greene D.A., Lattimer S.A., and Sima A.A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. New England Journal of Medicine 316 (1987) 599-606
8. Greene D.A., Sima A.A., Stevens M.J., Feldman E.L., and Lattimer S.A. Complications: Neuropathy, pathogenetic considerations. Diabetes Care 15 (1992) 1902-1925
9. Hamada Y., Odagaki Y., Sakakibara F., Naruse K., Koh N., and Hotta N. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. Life Sciences 57 (1995) 23-29
10. Hotta N., Toyota T., Matsuoka K., Shigeta Y., Kikkawa R., Kaneko T., Takahashi A., Sugimura K., Koike Y., Ishii J., and Sakamoto N. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24 (2001) 1776-1782
11. Malone J.I., Knox G., Benford S., and Tedesco T.A. Red cell sorbitol: An indicator of diabetic control. Diabetes 29 (1980) 861-864
12. Nakayama M., Nakamura J., Hamada Y., Chaya S., Mizubayashi R., Yasuda Y., Kamiya H., Koh N., and Hotta N. Aldose reductase inhibition ameliorates papillary light reflex and F-wave latency in patients with mile diabetic neuropathy. Diabetes Care 24 (2001) 1093-1098
13. Pfeifer M.A., Schumer M.P., and Gelber D.A. Aldose reductase inhibitors: The end of an era or the need for different trial designs?. Diabetes 46 Suppl. 2 (1997) S82-S89
14. Sima A.A., and Sugimoto K. Experimental diabetic neuropathy: An update. Diabetologia 42 (1999) 773-788
15. Stevens M.J. Nitric oxide as a potential bridge between the metabolic and vascular hypotheses of diabetic neuropathy. Diabetic Medicine 12 (1995) 292-295
16. Tilton R.G., Chang K., Hasan K.S., et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42 (1993) 221-232
17. Vinik A.I., Pittenger G.L., McNitt P., and Stansberry K.B. Diabetic neuropathies: An overview of clinical aspects, pathogenesis, and treatment. In: LeRoith D., Taylor S.I., and Olefsky J.M. (Eds). Diabetes mellitus. 2nd ed. (2000), Lippincott Williams and Wilkins, Philadelphia 910-934
18. Zochodne D.W. Diabetic neuropathies: Features and mechanisms. Brain Pathology 9 (1999) 369-391